News & Events
Rehovot, Israel, April 12, 2011 - Dynamix Pharmaceuticals, a drug discovery and development biopharmaceutical company focused on novel small-molecule drugs for cancer and autoimmune diseases, announced today that it will present a poster entitled “Modulation of cancer metabolism with novel PKM2 activators exerts anti-tumor activity” at the ASCO 2011 Annual Meeting, in Chicago, Illinois. The poster (#10530) will be presented on Saturday June 4, 2011 between 2:00 PM – 6:00 PM, in Exhibit Hall McCormick Place, S103. The poster will also be discussed in a “Poster Discussion Session” on Tumor Biology, Saturday June 4, 2011 at 5:00PM - 6:00PM, in McCormick Place S100bc. Dr. Oren Becker, President & CEO of Dynamix, will also attend the conference.
About the PKM2 program
Pyruvate Kinase M2 (PKM2) is one of four pyruvate kinase isoenzymes that catalyze the last step in glycolysis. Over expressed in cancer cells, PKM2 is a key mediator of the abnormal metabolism of cancer cells, known as the Warburg effect. Dynamix is developing a new class of small molecule drugs that activate PKM2 and renormalize the metabolism of cancer cells, thus offering a novel strategy for anti-cancer treatment.
About Dynamix Pharmaceuticals
Dynamix is a venture-backed biopharmaceutical company focused on the discovery and development of novel, targeted, small-molecule drugs for cancer and autoimmune disorders. Dynamix focuses on two drug classes – Cancer Metabolism modulators and Type II Selective Kinase Inhibitors. Both drug classes explore some of the newest and most promising therapeutic routes to treat urgent, unmet medical needs in cancer and autoimmune disorders. Founded in 2009, Dynamix has already created a strong pipeline of novel drug candidates, and is currently focusing on the optimization and preclinical development of these candidates. The company plans to start clinical development of its lead programs in 2011. This home grown pipeline was created with the company’s innovative proprietary DynamixFit™ technology, which is uniquely suitable for discovering novel kinase inhibitors, significantly shortens drug development times and lowers R&D costs.
Dr. Oren M. Becker
President and CEO
Dynamix Pharmaceuticals Ltd.